A positive ICOS signature may indicate a better clinical outcome of anti-CTLA-4 immune therapy in HPV-positive head and neck squamous cell carcinoma and EBV-positive stomach adenocarcinoma patients32. This evidence concerns the gene CTLA4 and gastric adenocarcinoma.